Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Glucose Regulation During Risperidone and Olanzapine Treatment
- Conditions
- First Posted Date
- 2000-09-08
- Last Posted Date
- 2006-10-12
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00006195
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
- Conditions
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 25
- Registration Number
- NCT00001656
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Treatment for First-Episode Schizophrenia
- Conditions
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 125
- Registration Number
- NCT00000374
- Locations
- 🇺🇸
Bronx-Lebanon Hospital Center, Bronx, New York, United States
🇺🇸Hillside Hospital, Glen Oaks, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.